MUC1 antibody-based therapeutics: the promise of cancer immunotherapy

References

• 1. Linden S, Sutton P, Karlsson N, Korolik V, Mcguckin M. Mucins in the mucosal barrier to infection. Mucosal Immunol. 1(3), 183–197 (2008).
  Medline CASGoogle Scholar
• 2. Ostedgaard LS, Moninger TO, Mcmenimen JD et al. Gel-forming mucins form distinct morphologic structures in airways. Proc. Natl Acad. Sci. USA 114(26), 6842–6847 (2017).
  Medline CASGoogle Scholar
• 3. Rachagani S, Torres MP, Moniaux N, Batra SK. Current status of mucins in the diagnosis and therapy of cancer. Biofactors 35(6), 509–527 (2009).
  Medline CASGoogle Scholar
• 4. Horm TM, Schroeder JA. MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh. Migr. 7(2), 187–198 (2013).
  MedlineGoogle Scholar
• 5. Dhar P, Mcauley J. The role of the cell surface mucin MUC1 as a barrier to infection and regulator of inflammation. Front. Cell. Infect. Microbiol. 9, 117 (2019).
  Medline CASGoogle Scholar
• 6. Parry S, Silverman HS, Mcdermott K, Willis A, Hollingsworth MA, Harris A. Identification of MUC1 proteolytic cleavage sites in vivo. Biochem. Biophys. Res. Commun. 283(3), 715–720 (2001).
  Medline CASGoogle Scholar
• 7. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22(6), 736–756 (2012).
  Medline CASGoogle Scholar
• 8. Movahedin M, Brooks TM, Supekar NT, Gokanapudi N, Boons G-J, Brooks CL. Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen. Glycobiology 27(7), 677–687 (2017).
  Medline CASGoogle Scholar
• 9. Piyush T, Rhodes JM, Yu L-G. MUC1 O-glycosylation contributes to anoikis resistance in epithelial cancer cells. Cell Death Discov. 3, 17044 (2017).
  Medline CASGoogle Scholar
• 10. Lan MS, Batra SK, Qi WN, Metzgar RS, Hollingsworth MA. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J. Biol. Chem. 265(25), 15294–15299 (1990).
  Medline CASGoogle Scholar
• 11. Parry S, Hanisch FG, Leir S-H et al. N-Glycosylation of the MUC1 mucin in epithelial cells and secretions. Glycobiology 16(7), 623–634 (2006).
  Medline CASGoogle Scholar
• 12. Tian E, Ten Hagen KG. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconj. J. 26(3), 325–334 (2009).
  Medline CASGoogle Scholar
• 13. Ju T, Wang Y, Aryal RP et al. T n and sialyl-Tn antigens, aberrant O-glycomics as human disease markers. Proteom. Clin. Appl. 7(9–10), 618–631 (2013).
  Medline CASGoogle Scholar
• 14. Clausen H, Bennett EP. A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation. Glycobiology 6(6), 635–646 (1996).
  Medline CASGoogle Scholar
• 15. Breloy I, Hanisch FG. Functional Roles of O-Glycosylation. Molecules 23(12), 3063 (2018).
  Google Scholar
• 16. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 7(6), 599–604 (2006).
  Medline CASGoogle Scholar
• 17. Hanson RL, Hollingsworth MA. Functional consequences of differential O-glycosylation of MUC1, MUC4, and MUC16 (downstream effects on signaling). Biomolecules 6(3), 34 (2016).
  Google Scholar
• 18. Chandrasekaran E, Xue J, Xia J et al. Characterization of cancer associated mucin type O-glycans using the exchange sialylation properties of mammalian sialyltransferase ST3Gal-II. J. Proteome Res. 11(4), 2609–2618 (2012).
  Medline CASGoogle Scholar
• 19. Saeland E, Belo AI, Mongera S, Van Die I, Meijer GA, Van Kooyk Y. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int. J. Cancer 131(1), 117–128 (2012).
  Medline CASGoogle Scholar
• 20. Taylor-Papadimitriou J, Burchell JM, Graham R, Beatson R. Latest developments in MUC1 immunotherapy. Biochem. Soc. Trans. 46(3), 659–668 (2018).
  Medline CASGoogle Scholar
• 21. Burchell J, Gendler S, Taylor-Papadimitriou J et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 47(20), 5476–5482 (1987).
  Medline CASGoogle Scholar
• 22. Posey AD Jr, Schwab RD, Boesteanu AC et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 44(6), 1444–1454 (2016).
  Medline CASGoogle Scholar
• 23. Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell 148(6), 1081–1084 (2012).
  Medline CASGoogle Scholar
• 24. Pourjafar M, Samadi P, Khoshinani HM, Saidijam M. Are mimotope vaccines a good alternative to monoclonal antibodies? Immunotherapy 11(9), 795–800 (2019).
  CASGoogle Scholar
• 25. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 12, 14 (2012).
  MedlineGoogle Scholar
• 26. Sameri S, Saidijam M, Bahreini F, Najafi R. Cancer chemopreventive activities of silibinin on colorectal cancer through regulation of E-cadherin/β-catenin pathway. Nutr. Cancer 1–11 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 27. Redman J, Hill E, Aldeghaither D, Weiner L. Mechanisms of action of therapeutic antibodies for cancer. Mol. Immunol. 67(2), 28–45 (2015).
  Medline CASGoogle Scholar
• 28. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin. Cancer Biol. 22(1), 3–13 (2012).
  Medline CASGoogle Scholar
• 29. Xu H, Gan L, Han Y et al. Site-specific labeling of an anti-MUC1 antibody: probing the effects of conjugation and linker chemistry on the internalization process. RSC Adv. 9(4), 1909–1917 (2019).
  CASGoogle Scholar
• 30. Xing P-X, Prenzoska J, Quelch K, Mckenzie IF. Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res. 52(8), 2310–2317 (1992).
  Medline CASGoogle Scholar
• 31. Rivalland G, Loveland B, Mitchell P. Update on Mucin-1 immunotherapy in cancer: a clinical perspective. Expert Opin. Biol. Ther. 15(12), 1773–1787 (2015).
  Medline CASGoogle Scholar
• 32. Murawa P, Kobylarek R, Gracz A, Malicki J, Kierzkowski J. Intraperitoneal administration of radiolabelled monoclonal antibody pemtumomab (Yttrium-90-HMFG1) in gastric cancer. Rep. Pract. Oncol. Radiother. 8(2), 49–56 (2003).
  Google Scholar
• 33. Xing PX, Tjandra J, Stacker S et al. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol. Cell Biol. 67(3), 183–195 (1989).
  MedlineGoogle Scholar
• 34. Pericleous L, Richards J, Epenetos A, Courtenay-Luck N, Deonarain M. Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1. Br. J. Cancer 93(11), 1257 (2005).
  Medline CASGoogle Scholar
• 35. Pegram MD, Borges VF, Ibrahim N et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 11(5), R73 (2009).
  MedlineGoogle Scholar
• 36. Ibrahim NK, Yariz KO, Bondarenko I et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor–positive locally advanced or metastatic breast cancer. Clin. Cancer. Res. 17(21), 6822–6830 (2011).
  Medline CASGoogle Scholar
• 37. Corraliza-Gorjón I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, Kremer L. New strategies using antibody combinations to increase cancer treatment effectiveness. Front. Immunol. 8, 1804 (2017).
  MedlineGoogle Scholar
• 38. Nagata M, Muto S, Horie S. Molecular biomarkers in bladder cancer: novel potential indicators of prognosis and treatment outcomes. Dis. Markers 2016, 8205836 (2016).
  MedlineGoogle Scholar
• 39. Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int. J. Cancer 57(2), 204–210 (1994).
  Medline CASGoogle Scholar
• 40. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin. Cancer Res. 13(24), 7380–7387 (2007).
  Medline CASGoogle Scholar
• 41. Gold DV, Newsome G, Liu D, Goldenberg DM. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol. Cancer 12(1), 143 (2013).
  MedlineGoogle Scholar
• 42. Cardillo TM, Ying Z, Gold DV. Therapeutic advantage of 90yttrium-versus 131iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin. Cancer Res. 7(10), 3186–3192 (2001).
  Medline CASGoogle Scholar
• 43. Gold DV, Cardillo T, Vardi Y, Blumenthal RJIJOC. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. Int. J. Cancer 71(4), 660–667 (1997).
  Medline CASGoogle Scholar
• 44. Gold DV, Cardillo T, Goldenberg DM, Sharkey RM. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit. Rev. Oncol. Hematol. 39(1–2), 147–154 (2001).
  Medline CASGoogle Scholar
• 45. Gulec S, Pennington K, Bruetman D et al. A Phase-I study of 90Y-hPAM4 (humanized anti-MUC1 monoclonal antibody) in patients with unresectable and metastatic pancreatic cancer. J. Nucl. Med. 48(Suppl. 2), 393P–393P (2007).
  Google Scholar
• 46. Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinform. 14(1), 42–54 (2016).
  MedlineGoogle Scholar
• 47. Picozzi VJ, Ramanathan RK, Lowery MA et al. 90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: a Phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Eur. J. Cancer 51(14), 1857–1864 (2015).
  Medline CASGoogle Scholar
• 48. Curry JM, Thompson KJ, Rao SG et al. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J. Surg. Oncol. 107(7), 713–722 (2013).
  Medline CASGoogle Scholar
• 49. Vivero-Escoto JL, Jeffords LM, Dréau D, Alvarez-Berrios M, Mukherjee P. Mucin1 antibody-conjugated dye-doped mesoporous silica nanoparticles for breast cancer detection in vivo. Presented at: Colloidal Nanoparticles for Biomedical Applications XII. San Francisco, CA, USA (2017).
  Google Scholar
• 50. Moore LJ, Roy LD, Zhou R et al. Antibody-guided in vivo imaging for early detection of mammary gland tumors. Transl. Oncol. 9(4), 295–305 (2016).
  MedlineGoogle Scholar
• 51. Bose M, Mukherjee P. A novel antibody blocks anti-apoptotic activity of MUC1 in pancreatic cancer cell lines. Cancer Res. 79(Suppl. 13), 2052 (2019).
  Google Scholar
• 52. Ilovich O, Kelly V, Wu S et al. Development and non-clinical evaluation of an 111In/225Ac theranostic for triple negative breast cancer. J. Med. Imaging Radiat. Oncol. 50, S113 (2019).
  Google Scholar
• 53. Ceriani RL, Chan CM, Baratta FS, Ozzello L, Derosa CM, Habif DV. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int. J. Cancer 51(3), 343–354 (1992).
  Medline CASGoogle Scholar
• 54. Mizrachi H, Salako QA, Furmanski P, Glenn SD, Denardo GL. Radioimmunolocalization of metastatic breast carcinoma using Indium-ill-Methyl Benzyl DTPA BrE-3 monoclonal antibody: Phase I study. J. Nucl. Med. 34(7), 1067–1074 (1993).
  MedlineGoogle Scholar
• 55. Denardo SJ, Kramer EL, O'donnell RT et al. Radioimmunotherapy for breast cancer using indium-lll/yttrium-90 BrE-3: results of a phase I clinical trial. J. Nucl. Med. 38(8), 1180–1185 (1997).
  Medline CASGoogle Scholar
• 56. Denardo SJ. Radioimmunodetection and therapy of breast cancer. Presented at: Semin. Nucl. Med. 35(2), 143–151 (2005).
  MedlineGoogle Scholar
• 57. Kramer EL, Liebes L, Wasserheit C et al. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin. Cancer. Res. 4(7), 1679–1688 (1998).
  Medline CASGoogle Scholar
• 58. Pietersz GA, Wenjun L, Krauer K, Baker T, Wreschner D, Mckenzie IF. Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Cancer Immunol. Immunother. 44(6), 323–328 (1997).
  Medline CASGoogle Scholar
• 59. Davies Q, Perkins A, Roos J et al. An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma. Br. J. Obstet. Gynaecol. 106(1), 31–37 (1999).
  Medline CASGoogle Scholar
• 60. Gillespie A, Broadhead T, Chan S et al. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann. Oncol. 11(6), 735–741 (2000).
  Medline CASGoogle Scholar
• 61. Chan SY, Gordon AN, Coleman RE et al. A Phase II study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol. Immunother. 52(4), 243–248 (2003).
  Medline CASGoogle Scholar
• 62. Price M, Pugh J, Hudecz F et al. C595–a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br. J. Cancer 61(5), 681 (1990).
  Medline CASGoogle Scholar
• 63. Song EY, Qu CF, Rizvi SM et al. Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol. Ther. 7(1), 76–80 (2008).
  Medline CASGoogle Scholar
• 64. Hughes O, Bishop M, Perkins A et al. Targeting superficial bladder cancer by the intravesical administration of copper-67–labeled anti-MUC1 mucin monoclonal antibody C595. J. Clin. Oncol. 18(2), 363–363 (2000).
  Medline CASGoogle Scholar
• 65. Hughes O, Perkins A, Frier M et al. Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. BJU Int. 87(1), 39–46 (2001).
  Medline CASGoogle Scholar
• 66. Dian D, Janni W, Kuhn C et al. Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies. Oncol. Res. Treat. 32(5), 238–244 (2009).
  CASGoogle Scholar
• 67. Danielczyk A, Stahn R, Faulstich D et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol. Immunother. 55(11), 1337–1347 (2006).
  Medline CASGoogle Scholar
• 68. Fiedler W, Dedosso S, Cresta S et al. A Phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. Eur. J. Cancer 63, 55–63 (2016).
  Medline CASGoogle Scholar
• 69. Ledermann J, Sehouli J, Zurawski B et al. LBA41A double-blind, placebo-controlled, randomized, Phase II study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma. Ann. Oncol. 28(Suppl. 5), 626 (2017).
  Google Scholar
• 70. Garralda E, Van Hoef M, Ochsenreither S et al. 1510TiP The GATTO study: a Phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. Ann. Oncol. 29, 292–131 (2018).
  MedlineGoogle Scholar
• 71. Qi W, Schultes BC, Liu D, Kuzma M, Decker W, Madiyalakan R. Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybridoma Hybridomics 20(5–6), 313–324 (2001).
  Medline CASGoogle Scholar
• 72. De Bono J, Rha SY, Stephenson J et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann. Oncol. 15(12), 1825–1833 (2004).
  MedlineGoogle Scholar
• 73. Mehla K, Tremayne J, Grunkemeyer JA et al. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors. Cancer Immunol. Immunother. 67(3), 445–457 (2018).
  Medline CASGoogle Scholar
• 74. Kearse KP, Smith NL, Semer DA et al. Monoclonal antibody DS6 detects a tumor-associated sialoglycotope expressed on human serous ovarian carcinomas. Int. J. Cancer 88(6), 866–872 (2000).
  Medline CASGoogle Scholar
• 75. Trombe M, Caron A, Tellier A et al. Preclinical activity of an antibody drug conjugate targeting tumor specificmuc1 structural peptide-glycotope. Cancer Res. 79(Suppl. 13), 235 (2019).
  Google Scholar
• 76. Gomez-Roca CA, Boni V, Moreno V et al. A Phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870). J. Clin. Oncol. 34(Suppl. 15), 2511 (2016).
  Google Scholar
• 77. Calvete JA, Newell DR, Wright AF, Rose MS. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer. Cancer Res. 54(17), 4684–4690 (1994).
  Medline CASGoogle Scholar
• 78. Baeckström D, Hansson GC, Nilsson O, Johansson C, Gendler SJ, Lindholm L. Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J. Biol. Chem. 266(32), 21537–21547 (1991).
  Medline CASGoogle Scholar
• 79. Tolcher AW, Ochoa L, Hammond LA et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a Phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 21(2), 211–222 (2003).
  Medline CASGoogle Scholar
• 80. Rodon J, Garrison M, Hammond LA et al. Cantuzumab mertansine in a three-times a week schedule: a Phase I and pharmacokinetic study. Cancer Chemother. Pharmacol. 62(5), 911–919 (2008).
  Medline CASGoogle Scholar
• 81. Mita M, Ricart A, Mita A et al. A Phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors. J. Clin. Oncol. 25(Suppl. 18), 3062–3062 (2007).
  Google Scholar
• 82. Goff L, Papadopoulos K, Posey J et al. A Phase II study of IMGN242 (huC242-DM4) in patients with CanAg-positive gastric or gastroesophageal (GE) junction cancer. J. Clin. Oncol. 27(15S), e15625–e15625 (2009).
  Google Scholar
• 83. Biassoni L, Granowska M, Carroll M et al. 99m Tc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection. Br. J. Cancer 77(1), 131 (1998).
  Medline CASGoogle Scholar
• 84. You F, Jiang L, Zhang B et al. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Sci. China Life Sci. 59(4), 386–397 (2016).
  Medline CASGoogle Scholar
• 85. Paknejad M, Rasaee M, Tehrani FK et al. Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin. Hybridoma Hybridomics 22(3), 153–158 (2003).
  Medline CASGoogle Scholar
• 86. Mohammadi M, Rasaee MJ, Rajabibazl M, Paknejad M, Zare M, Mohammadzadeh S. Epitope mapping of PR81 anti-MUC1 monoclonal antibody following PEPSCAN and phage display techniques. Hybridoma 26(4), 223–230 (2007).
  Medline CASGoogle Scholar
• 87. Salouti M, Rajabi H, Babaei M et al. 99mTc direct radiolabeling of PR81, a new anti-MUC1 monoclonal antibody for radioimmunoscintigraphy. Iran. J. Nucl. Med. 13(1), 7–16 (2005).
  Google Scholar
• 88. Nishimura S-I, Hinou H, Numata Y, Onoda J, Naito S, Ohyabu N. Anti-MUC1 antibody. (U.S. Patent No. 8,722,856) (2014).
  Google Scholar
• 89. Pelat T, Hust M, Hale M, Lefranc M-P, Dübel S, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol. 9(1), 60 (2009).
  MedlineGoogle Scholar
• 90. Thie H, Toleikis L, Li J et al. Rise and fall of an anti-MUC1 specific antibody. PLoS ONE 6(1), e15921 (2011).
  Medline CASGoogle Scholar
• 91. Yonezawa S, Kitajima S, Higashi M et al. A novel anti-MUC1 antibody against the MUC1 cytoplasmic tail domain: use in sensitive identification of poorly differentiated cells in adenocarcinoma of the stomach. Gastric Cancer 15(4), 370–381 (2012).
  Medline CASGoogle Scholar
• 92. Ismaili A, Jalali-Javaran M, Rasaee MJ, Rahbarizadeh F, Forouzandeh-Moghadam M, Memari HR. Production and characterization of anti-(mucin MUC1) single-domain antibody in tobacco (Nicotiana tabacum cultivar Xanthi). Biotechnol. Appl. Biochem. 47(1), 11–19 (2007).
  Medline CASGoogle Scholar
• 93. Sadeqzadeh E, Rahbarizadeh F, Ahmadvand D, Rasaee MJ, Parhamifar L, Moghimi SM. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. J. Control. Release 156(1), 85–91 (2011).
  Medline CASGoogle Scholar
• 94. Pichinuk E, Benhar I, Jacobi O et al. Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells. Cancer Res. 72(13), 3324–3336 (2012).
  Medline CASGoogle Scholar
• 95. Rubinstein DB, Karmely M, Ziv R et al. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 A/B junction antibodies that target malignant cells. Cancer Res. 66(23), 11247–11253 (2006).
  Medline CASGoogle Scholar
• 96. Panchamoorthy G, Jin C, Raina D et al. Targeting the human MUC1-C oncoprotein with an antibody–drug conjugate. JCI Insight 3(12), e99880 (2018).
  MedlineGoogle Scholar
• 97. Wu G, Kim D, Kim JN et al. A Mucin1 C-terminal subunit-directed monoclonal antibody targets overexpressed Mucin1 in breast cancer. Int. J. Mol. Sci. 8(1), 78 (2018).
  CASGoogle Scholar
• 98. Wu G, Maharjan S, Kim D et al. A novel monoclonal antibody targets mucin1 and attenuates growth in pancreatic cancer model. Int. J. Mol. Sci. 19(7), 2004 (2018).
  Google Scholar
• 99. Kim MJ, Choi JR, Tae N et al. Novel antibodies targeting MUC1-C showed anti-metastasis and growth-inhibitory effects on human breast cancer cells. Int. J. Mol. Sci. 21(9), 3258 (2020).
  CASGoogle Scholar
• 100. Naito S, Takahashi T, Onoda J et al. Generation of novel anti-MUC1 monoclonal antibodies with designed carbohydrate specificities using MUC1 glycopeptide library. ACS Omega 2(11), 7493–7505 (2017).
  Medline CASGoogle Scholar
• 101. Palitzsch B, Gaidzik N, Stergiou N et al. A synthetic glycopeptide vaccine for the induction of a monoclonal antibody that differentiates between normal and tumor mammary cells and enables the diagnosis of human pancreatic cancer. Angew. Chem. Int. 55(8), 2894–2898 (2016).
  Medline CASGoogle Scholar
• 102. Stergiou N, Nagel J, Pektor S et al. Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer. Int. J. Med. Sci. 16(9), 1188 (2019).
  Medline CASGoogle Scholar
• 103. Wakui H, Tanaka Y, Ose T et al. A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes. Chem. Sci. 11(19), 4999–5006 (2020).
  Medline CASGoogle Scholar
• 104. Doi M, Yokoyama A, Kondo K et al. Anti-tumor effect of the anti-KL-6/MUC1 monoclonal antibody through exposure of surface molecules by MUC1 capping. Cancer Sci. 97(5), 420–429 (2006).
  Medline CASGoogle Scholar
• 105. Ohyabu N, Hinou H, Matsushita T et al. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. J. Am. Chem. Soc. 131(47), 17102–17109 (2009).
  Medline CASGoogle Scholar
• 106. Namba M, Hattori N, Hamada H et al. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1. Cancer Lett. 442, 31–39 (2019).
  Medline CASGoogle Scholar
• 107. Matsumura K, Niki I, Tian H et al. Radioimmunoscintigraphy of pancreatic cancer in tumor-bearing athymic nude mice using 99m technetium-labeled anti-KL-6/MUC1 antibody. Radiat. Med. 26(3), 133 (2008).
  Medline CASGoogle Scholar
• 108. Yamamoto M, Bhavanandan V, Nakamori S, Irimura T. A novel monoclonal antibody specific for sialylated MUC1 mucin. Jap. J. Cancer Res. 87(5), 488–496 (1996).
  Medline CASGoogle Scholar
• 109. Suzuki H, Shoda J, Kawamoto T et al. Expression of MUC1 recognized by monoclonal antibody MY. 1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma. Clin. Exp. Metastasis 21(4), 321–329 (2004).
  Medline CASGoogle Scholar
• 110. Yoshimura Y, Denda-Nagai K, Takahashi Y et al. Products of chemoenzymatic synthesis representing MUC1 tandem repeat unit with T-, ST-or STn-antigen revealed distinct specificities of anti-MUC1 antibodies. Sci. Rep. 9(1), 1–12 (2019).
  MedlineGoogle Scholar
• 111. Muguruma N, Ito S. Labeled anti-mucin antibody detectable by infrared-fluorescence endoscopy. Cancer Biomark. 4(6), 321–328 (2008).
  Medline CASGoogle Scholar
• 112. Ryuko K, Schol DJ, Snijdewint FG et al. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1. Tumor Biol. 21(4), 197–210 (2000).
  Medline CASGoogle Scholar
• 113. Tarp MA, Sørensen AL, Mandel U et al. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17(2), 197–209 (2007).
  Medline CASGoogle Scholar
• 114. Sørensen AL, Reis CA, Tarp MA et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 16(2), 96–107 (2006).
  Medline CASGoogle Scholar
• 115. Posey AD Jr, Schwab RD, Boesteanu AC et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 44(6), 1444–1454 (2016).
  Medline CASGoogle Scholar
• 116. King T, Posey A. Co-expression of an engineered cell-surface sialidase by CART cells improves anti-cancer activity of NK cells in solid tumors. Cytotherapy 21(5), S27 (2019).
  Google Scholar
• 117. Li Y, Zhou C, Li J et al. Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. PLoS ONE 13(1), e0191024 (2018).
  MedlineGoogle Scholar
• 118. Katayose Y, Kudo T, Suzuki M et al. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res. 56(18), 4205–4212 (1996).
  Medline CASGoogle Scholar
• 119. Hinoda Y, Nakagawa N, Ohe Y et al. Recognition of the polypeptide core of mucin by monoclonal antibody MUSE11 against an adenocarcinoma-associated antigen. Jap. J. Cancer Res. 81(12), 1206–1209 (1990).
  Medline CASGoogle Scholar
• 120. Takemura S-I, Asano R, Tsumoto K et al. Construction of a diabody (small recombinant bispecific antibody) using a refolding system. Protein Eng. 13(8), 583–588 (2000).
  Medline CASGoogle Scholar
• 121. Takemura S-I, Kudo T, Asano R et al. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol. Immunother. 51(1), 33–44 (2002).
  Medline CASGoogle Scholar
• 122. Runcie K, Budman DR, John V, Seetharamu NJMM. Bi-specific and tri-specific antibodies-the next big thing in solid tumor therapeutics. Mol. Med. 24(1), 50 (2018).
  MedlineGoogle Scholar
• 123. Goletz S, Kehler P, Gellert J, Danielczyk A, Jäkel A. Multispecific antibody constructs binding to muc1 and cd3. https://patents.google.com/patent/US20200131275A1/en (2020).
  Google Scholar
• 124. Kodama H, Suzuki M, Katayose Y et al. Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies. Immunol. Lett. 81(2), 99–106 (2002).
  Medline CASGoogle Scholar
• 125. Schuhmacher J, Klivényi G, Kaul S et al. Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl. Med. Biol. 28(7), 821–828 (2001).
  Medline CASGoogle Scholar
• 126. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9(12), 874–885 (2009).
  Medline CASGoogle Scholar
• 127. Thie H, Toleikis L, Li J et al. Rise and fall of an anti-MUC1 specific antibody. PLoS ONE 6(1), e15921 (2011).
  Medline CASGoogle Scholar
• 128. Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, Von Mensdorff-Pouilly S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett. 257(1), 47–55 (2007).
  Medline CASGoogle Scholar
• 129. Tang Y, Cui X, Xiao H et al. Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer. Mol. Med. Rep. 15(5), 2659–2664 (2017).
  Medline CASGoogle Scholar
• 130. Treon SP, Maimonis P, Bua D et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 96(9), 3147–3153 (2000).
  Medline CASGoogle Scholar
• 131. Storr SJ, Royle L, Chapman CJ et al. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology 18(6), 456–462 (2008).
  Medline CASGoogle Scholar
• 132. Pegram M, Borges V, Fuloria J et al. Phase I pharmacokinetics (PK) of humanized anti-MUC-1 antibody R1550. J. Clin. Oncol. 24(Suppl. 18), 2533–2533 (2006).
  Google Scholar
• 133. Zhou D, Xu L, Huang W, Tonn T. Epitopes of MUC1 tandem repeats in cancer as revealed by antibody crystallography: toward glycopeptide signature-guided therapy. Molecules 23(6), 1326 (2018).
  Google Scholar
• 134. Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol. Ther. 6(4), 481–486 (2007).
  Medline CASGoogle Scholar
• 135. Ledermann J, Sehouli J, Zurawski B et al. LBA41A double-blind, placebo-controlled, randomized, Phase II study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma. 28(Suppl. 5), (2017).
  Google Scholar
• 136. Madsen CB, Wandall HH, Pedersen AE. Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy. Immunopharmacol. Immunotoxicol. 35(6), 649–652 (2013).
  Medline CASGoogle Scholar
• 137. Zhao Q, Piyush T, Chen C et al. MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis. Cell Death Dis. 5(10), e1438–e1438 (2014).
  Medline CASGoogle Scholar
• 138. Mcguckin MA, Hurst TG, Ward BG. Heterogeneity in production, secretion and glycosylation of MUC1 epithelial mucin by primary cultures of ovarian carcinoma. Int. J. Cancer 63(3), 412–418 (1995).
  Medline CASGoogle Scholar
• 139. Walsh MD, Luckie SM, Cummings MC, Antalis TM, Mcguckin MA. Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res. Treat. 58(3), 253–264 (1999).
  Google Scholar
• 140. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Clin. Pharmacokinet. 28(2), 126–142 (1995).
  Medline CASGoogle Scholar